Data completeness
2/8 — Basic
HYDROMOX R (quinethazone; reserpine) by Pfizer is insulin, including humulin r, is the regulation of glucose metabolism. Approved for glycemic control in adult.
Drug data last refreshed 27m ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDROMOX R is an oral tablet combining quinethazone and reserpine for glycemic control in adults with diabetes. The product regulates glucose metabolism by stimulating peripheral glucose uptake and inhibiting hepatic glucose production. It represents a combination approach to blood sugar management in pre-launch development by Pfizer.
Pre-Launch
Early-stage pre-launch product with limited commercial trajectory data; team composition and size to be determined post-approval.
Mechanism of Action
insulin, including HUMULIN R, is the regulation of glucose metabolism. Insulin lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein…
Indications (1)
Career Relevance
HYDROMOX R is a pre-launch product offering early-career opportunities in regulatory approval navigation and launch planning. Career growth potential depends on successful FDA approval and competitive differentiation in a mature glycemic control market.
Worked on HYDROMOX R at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.